vs
Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and OFG BANCORP (OFG). Click either name above to swap in a different company.
Ascendis Pharma A/S is the larger business by last-quarter revenue ($267.3M vs $184.3M, roughly 1.5× OFG BANCORP). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 0.9%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 2.8%).
Ascendis Pharma A/SASNDEarnings & Financial Report
Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.
OFG Bancorp, founded in 1964, is the financial holding company for Oriental Bank, located in San Juan, Puerto Rico. OFG offers a wide range of retail and commercial banking, lending and wealth management products, services and technology, primarily in Puerto Rico and the U.S. Virgin Islands through its principal subsidiaries: Oriental Bank, Oriental Financial Services LLC, and Oriental Insurance LLC. Its headquarters are located at Oriental Center, 254 Muñoz Rivera Avenue, San Juan, PR 00918....
ASND vs OFG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $267.3M | $184.3M |
| Net Profit | — | $55.9M |
| Gross Margin | 90.5% | — |
| Operating Margin | — | 25.7% |
| Net Margin | — | 30.3% |
| Revenue YoY | 42.3% | 0.9% |
| Net Profit YoY | — | 11.0% |
| EPS (diluted) | — | $1.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $267.3M | $184.3M | ||
| Q3 25 | $230.7M | $186.2M | ||
| Q2 25 | $170.7M | $182.4M | ||
| Q1 25 | $109.0M | $178.6M | ||
| Q4 24 | $187.8M | $182.7M | ||
| Q3 24 | $62.5M | $174.7M | ||
| Q2 24 | $38.9M | $179.8M | ||
| Q1 24 | $103.6M | $174.4M |
| Q4 25 | — | $55.9M | ||
| Q3 25 | $-65.9M | $51.8M | ||
| Q2 25 | $-42.0M | $51.8M | ||
| Q1 25 | $-102.2M | $45.6M | ||
| Q4 24 | — | $50.3M | ||
| Q3 24 | $-107.1M | $47.0M | ||
| Q2 24 | $-118.1M | $51.1M | ||
| Q1 24 | $-141.5M | $49.7M |
| Q4 25 | 90.5% | — | ||
| Q3 25 | 89.5% | — | ||
| Q2 25 | 80.1% | — | ||
| Q1 25 | 82.6% | — | ||
| Q4 24 | 91.9% | — | ||
| Q3 24 | 80.6% | — | ||
| Q2 24 | 68.2% | — | ||
| Q1 24 | 92.1% | — |
| Q4 25 | — | 25.7% | ||
| Q3 25 | 5.1% | 33.0% | ||
| Q2 25 | -33.5% | 36.1% | ||
| Q1 25 | -103.2% | 33.3% | ||
| Q4 24 | — | 28.9% | ||
| Q3 24 | -167.3% | 35.4% | ||
| Q2 24 | -370.2% | 39.6% | ||
| Q1 24 | -51.2% | 38.9% |
| Q4 25 | — | 30.3% | ||
| Q3 25 | -28.5% | 27.8% | ||
| Q2 25 | -24.6% | 28.4% | ||
| Q1 25 | -93.7% | 25.5% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | -171.5% | 26.9% | ||
| Q2 24 | -303.9% | 28.4% | ||
| Q1 24 | -136.6% | 28.5% |
| Q4 25 | — | $1.27 | ||
| Q3 25 | — | $1.16 | ||
| Q2 25 | — | $1.15 | ||
| Q1 25 | — | $1.00 | ||
| Q4 24 | — | $1.10 | ||
| Q3 24 | — | $1.00 | ||
| Q2 24 | — | $1.08 | ||
| Q1 24 | — | $1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $665.3M | $1.0B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-175.8M | $1.4B |
| Total Assets | $1.4B | $12.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $665.3M | $1.0B | ||
| Q3 25 | $582.2M | $740.3M | ||
| Q2 25 | $533.6M | $851.8M | ||
| Q1 25 | $559.4M | $710.6M | ||
| Q4 24 | $604.3M | $591.1M | ||
| Q3 24 | $675.6M | $680.6M | ||
| Q2 24 | $279.4M | $740.4M | ||
| Q1 24 | $345.9M | $754.4M |
| Q4 25 | $-175.8M | $1.4B | ||
| Q3 25 | $-188.0M | $1.4B | ||
| Q2 25 | $-202.6M | $1.3B | ||
| Q1 25 | $-205.0M | $1.3B | ||
| Q4 24 | $-114.2M | $1.3B | ||
| Q3 24 | $-105.1M | $1.3B | ||
| Q2 24 | $-346.8M | $1.2B | ||
| Q1 24 | $-257.2M | $1.2B |
| Q4 25 | $1.4B | $12.5B | ||
| Q3 25 | $1.2B | $12.2B | ||
| Q2 25 | $1.2B | $12.2B | ||
| Q1 25 | $1.1B | $11.7B | ||
| Q4 24 | $1.3B | $11.5B | ||
| Q3 24 | $1.2B | $11.5B | ||
| Q2 24 | $819.0M | $11.3B | ||
| Q1 24 | $866.7M | $11.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $58.2M | $217.7M |
| Free Cash FlowOCF − Capex | — | $199.3M |
| FCF MarginFCF / Revenue | — | 108.1% |
| Capex IntensityCapex / Revenue | — | 10.0% |
| Cash ConversionOCF / Net Profit | — | 3.90× |
| TTM Free Cash FlowTrailing 4 quarters | — | $345.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.2M | $217.7M | ||
| Q3 25 | — | $39.5M | ||
| Q2 25 | — | $35.9M | ||
| Q1 25 | $-15.5M | $83.1M | ||
| Q4 24 | $-330.7M | $252.5M | ||
| Q3 24 | — | $58.1M | ||
| Q2 24 | — | $95.1M | ||
| Q1 24 | $-109.7M | $61.0M |
| Q4 25 | — | $199.3M | ||
| Q3 25 | — | $35.5M | ||
| Q2 25 | — | $31.8M | ||
| Q1 25 | — | $78.7M | ||
| Q4 24 | — | $231.2M | ||
| Q3 24 | — | $51.8M | ||
| Q2 24 | — | $90.4M | ||
| Q1 24 | — | $54.8M |
| Q4 25 | — | 108.1% | ||
| Q3 25 | — | 19.1% | ||
| Q2 25 | — | 17.4% | ||
| Q1 25 | — | 44.1% | ||
| Q4 24 | — | 126.5% | ||
| Q3 24 | — | 29.6% | ||
| Q2 24 | — | 50.3% | ||
| Q1 24 | — | 31.4% |
| Q4 25 | — | 10.0% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | — | 2.3% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | — | 3.6% | ||
| Q2 24 | — | 2.6% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | — | 3.90× | ||
| Q3 25 | — | 0.76× | ||
| Q2 25 | — | 0.69× | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 5.02× | ||
| Q3 24 | — | 1.24× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
